With a transparent pricing model$199 for the initial consultation and $99 per month for ongoing medication management, refills, and provider supportthe program offers a highly competitive alternative to traditional insurance-based treatments
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist that produces weight loss results between semaglutide and retatrutide, with approximately 20-22% average weight loss at the 15 mg dose
Still, a noticeable number of people report warmth, flushing, or vasomotor sensations while on the drug, so the relationship deserves careful tracking rather than dismissal
Vitamin B12 is the main exception, as it can be stored in the liver for years
PCSK9 inhibitors, including monoclonal antibodies and RNA-based therapies, represent groundbreaking advancements, reshaping the LDL-C-lowering drug landscape